Tech Company Financing Transactions
TRiCares Funding Round
TRiCares, operating out of Paris, raised $47 million in funding from 415 CAPITAL, Andera Partners and BioMedPartners.
Transaction Overview
Company Name
Announced On
9/15/2022
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series C
Investors
415 CAPITAL (Lead Investor) (Frederik Groenewegen)
Andera Partners (Sofia Ioannidou)
Proceeds Purpose
The proceeds of this financing will primarily be used to continue the development of the company's transfemoral tricuspid heart valve replacement system ("Topaz") up through to the application for a pivotal investigational device exemption ("IDE") trial in the United States.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
27 Avenue de
Paris, 75001
FR
Paris, 75001
FR
Phone
Undisclosed
Website
Email Address
Overview
Developer of catheter-based valve replacement system designed for minimally invasive treatment of tricuspid valve regurgitation. The company's medical devices address tricuspid insufficiency through their anatomical conformation and their simplicity of use, enabling patients to avail of effective and lasting cures to the problem of tricuspid insufficiency.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Helmut Straubinger
Browse more venture capital transactions:
Prev: 9/14/2022: NeoCarbon venture capital transaction
Next: 9/15/2022: Turaco venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs